Sensodyne products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina, October 29, 2024. REUTERS
April 29 (Reuters) – British consumer healthcare group Haleon on Wednesday reported first quarter revenue growth slightly below analyst expectations, as weakness in other international markets offset growth in North America.
The Sensodyne maker reported organic revenue growth of 2.2% for the three months through March, compared to analysts’ expectations of 2.3%, according to the company-compiled consensus.
Reporting by Raechel Thankam Job in Bengaluru; Editing by Ronojoy Mazumdar
